Analysis of a variant translocation t(l1; 17) in a case of acute promyelocytic leukemia (APLI led to discovery of a novel tine finger gene, PLZF, fused to the retinoic acid receptor-cu (RARa) gene. We reviewed the clinical and molecular features of five additional patients with t(ll;l7)-associated APL. The clinical course of three patients was characterized by early death and three experienced disseminated intravascular coagulation. Morphologically all of the patients fell in a unusual morphologic spectrum of APL, with features intermediate between M 2 and M 3 AML. All six patients had PLZF-RARa gene fusion as detected by reverse transcription/polymerase chain reaction assay, Southern blotting, or OLECULAR ANALYSIS of chromosomal translocations associated with cancer have identified genes involved in the pathogenesis of neoplasia,' many of which encode DNA binding transcription factors.' Chromosomal rearrangements may lead to aberrant expression of these factors, as in the case of Burkitt's lymphoma associated with t(8; 14) and the fusion of the myc oncogene with the Ig heavy chain promoter.' Alternatively, chromosomal translocations may yield fusion genes encoding chimeric transcription factors with novel DNA binding or transcriptional effector properties.4-6 Acute promyelocytic leukemia (APL) is associated with the consistent chromosomal translocation t( 15; 17) fusing the promyelocytic leukemia (PML) and retinoic acid receptor-a (RARa) gene^.^.^ Cytogenetic or molecular evidence of this translocation is detected in 90% to 100% of patients with morphologically diagnosed APL. This disease is uniquely sensitive to treatment with all-trans retinoic acid (ATRA) yielding complete remission (CR) rates of 75% to 95%.10"3 APL is also highly responsive to conventional chemotherapy. Although the disease is associated with higher rates of early mortality, largely caused by coagulopathy, the long-term prognosis for APL is more favorable than other forms of acute myelogenous leukemia, with 5-year survival rates of 35% to 45%.I4.I5
OLECULAR ANALYSIS of chromosomal translocations associated with cancer have identified genes involved in the pathogenesis of neoplasia,' many of which encode DNA binding transcription factors.' Chromosomal rearrangements may lead to aberrant expression of these factors, as in the case of Burkitt's lymphoma associated with t (8; 14) and the fusion of the myc oncogene with the Ig heavy chain promoter.' Alternatively, chromosomal translocations may yield fusion genes encoding chimeric transcription factors with novel DNA binding or transcriptional effector properties.4-6 Acute promyelocytic leukemia (APL) is associated with the consistent chromosomal translocation t( 15; 17) fusing the promyelocytic leukemia (PML) and retinoic acid receptor-a (RARa) gene^.^.^ Cytogenetic or molecular evidence of this translocation is detected in 90% to 100% of patients with morphologically diagnosed APL. This disease is uniquely sensitive to treatment with all-trans retinoic acid (ATRA) yielding complete remission (CR) rates of 75% to 95%.10"3 APL is also highly responsive to conventional chemotherapy. Although the disease is associated with higher rates of early mortality, largely caused by coagulopathy, the long-term prognosis for APL is more favorable than other forms of acute myelogenous leukemia, with 5-year survival rates of 35% to 45%.I4. I5 The molecular pathology of t( 15; 17) APL may be largely explained by the chimeric PML-RARa transcription factor generated by the t( 15; 17) translocation. The PML-RARa fusion protein interferes with retinoic acid (RA)-and RARmediated t r a n s c r i p t i~n~~~~~'~ known to be important for normal myeloid differentiation.2'.22 When transduced into the model leukemia cell lines HL60 or U937, the PML-RARa fusion protein prevents differentiation of these cells in the presence of physiologic levels of ATRA (IO-' mom) and actually enhances differentiation in the presence of pharmacologic doses of ATRA This finding parallels the clinical observation that t( 15; 17) APL can be treated to CR in a high number of cases with ATRA alone. These remissions are not caused by the elimination of the malignant clone, but are rather caused by the induction of differentiation in the clinical setting. Peripheral blood granulocytes from patients with APL treated with ATRA still harbor the t(l5; 17) translocation and resulting PML-RARa fusion RNA,'2~'5~'8 suggesting that the malignant clone persists. This finding may explain the high rate of relapse of these patients when treated with ATRA alone without subsequent chemotherapy.
Recently, in a survey of Chinese patients with morphologically diagnosed APL (French-American-British [FAB] M3), a novel translocation t(l1; 17) (q23;q21) was identified. In a manner analogous to t( 15; 17) APL, t( 11; 17) creates novel fusion genes by linking the gene encoding RARa to a gene encoding a protein with 9 zinc finger motifs named PLZF (promyelocytic leukemia zinc fir~ger).~.'~ The index patient was treated with ATRA, but failed to respond to therapy.3o Subsequently, we have identified five other leukemic patients with the t( 11; 17) and fusion of the RARa and PLZF genes. Four of these additional patients were diagnosed with APL by morphology and one was identified from among a group of patients with leukemia bearing features of both myeloid and natural killer cells." Upon review, all of the cases were treated with 500 U/h of heparin and oral ciprofloxin and received oral ATRA at 45 mg/m2/d for a planned 30-day course. The WBC increased to 25 X lo9& with a decrease in the percentage of promyelocytes in peripheral smears. DIC improved so that there was only a slight elevation of fibrin split products and a near normal fibrinogen level by the time of death. The administration of ATRA led to lip chapping and headache. The patient also developed respiratory distress, which was initially attributed to pneumonia and treated with intravenous ceftazidime. After repiratory distress persisted, the retinoic acidpulmonary syndrome" and pulmonary edema were considered as etiologies but a ventilatiodperfusion scan showed multiple perfusion defects consistent with pulmonary emboli. An inferior vena cava filter was then placed. Despite a platelet count greater than 50 X loy& low levels of fibrin split products, and a normal fibrinogen level, the patient developed a spontaneous brain stem hemorrhage, diagnosed by computed tomography, and died on day 18 of therapy.
Case no. 4 (Albuquerque, NM). A 37-year-old American black woman presented in April 1991 with an HGB of 69 g/L, an HCT of 20%, a platelet count of 30 X loy& and a WBC of 45.2 X IO' (64% myelocytes, 16% segmented forms, 1 I % lymph, 4% monocytes, and 1% basophils). Pretreatment BM evaluation showed a myeloiderythroid ratio of 50:l with 47% blasts, 10% promyleocytes, 9% metamyelocytes, 3% bands, 5% lymphocytes, and 2% erythroid precursors (Fig ID) . The blasts stained positive for Sudan Black B and negative for a-napthyl butyrate and a-napthyl acetate. The patient was initially classified as M2 by the FAB criteria, although the peripheral blood showed leukocytosis with an arrest at the myelocyte stage reminiscent of a myeloproliferative disorder. Cytogenetic studies showed 46, XX t( 11; 17) (q23;q21). As determined by immunophenotyping, the leukemic blasts were CD33', CD13', CD56'. CD16-. The patient was treated with daunorubicin (45 mg/m*, days 1 through 3) and Ara-C (200 mg/m2, days 1 through 7) according to Southwest Oncology Group Protocol 8600, with complications of vaginal bleeding and gram-negative sepsis. After marrow recovery, BM examination in May 1991 showed 2% promyelocytes, 55% myelocytes, 13% metamyelocytes, and 18% segmented forms but no myeloblasts. Cytogenetic analysis showed the persistence of t( 1 1 ; 17) and no Philadelphia chromosome was detected. The patient was then treated with a-interferon (1 X 10' U/d) without effect. In August l99 1, she presented with fever, bone pain, and myeloblasts in the BM aspirate. She was treated with mitoxantrone (12 mg/m2, days 1 through 5) and etoposide (100 mg/m2, days 1 through 5), which induced a remission. In November 1991, she had an HCT of 35% and a WBC of 4.0 X lO'/L, with 1 % myelocytes in the differential count and no blasts seen. The patient was lost to further medical follow-up and died in March 1992. No autopsy was performed.
Case no. 5 (Paris, France). A 34-year-old French man presented with bone pain and neutropenia. The initial WBC was 2.4 X 10y/L, the platelets level was 168 X 10y/L, and the HGB was 127 g/L. There were 23% blasts in the peripheral blood. BM examination showed 63% myeloblasts with Auer rods and typical promyelocytic morphology (Fig 1E) . Cytogenetic analysis showed a t( 11; 17) and reverse transcriptiodpolymerase chain reaction (RTFCR) indicated the presence of a fusion between the PLZF and RAR-a genes. The patient was randomized to a protocol arm containing 31 days of oral ATRA (45 mg/m2 on days 1 through 31). followed by daunorubicin (60 mg/m' on days 3 through 5) and Ara-C (200 mg/m2 on days 3 through 9). During the first 5 days of treatment, the WBC count remained stable, but the percentage of blasts in the peripheral blood increased to 59%. By day 8, peripheral blasts disappeared secondary to myeloablative therapy. At diagnosis, mild DIC was present, without complication of skin or mucosal bleeding. The PT was 17.5 seconds (l 1.6 seconds for the control) and fibrin split products were elevated at a dilution of between 1/64 and 111,024. D-dimers were detected at a 1/32 dilution and the fibrinogen level was 800 mg/L.
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From The patient received low-dose heparin at 100 mg/kg/d on days 4 seconds (1 1.6 seconds for the control); fibrin split products were through 26 of treatment. DIC persisted in the absence of peripheral detected at a dilution of 11256 and D-dimers at a 1/16 dilution. The blasts and marrow examination at day 11 showed 95% blasts. BM patient was then treated with amsacrine, (225 mg/m2 on days 1 examination on day 17 showed the persistence of blasts. DIC also through 3) and high-dose h a -C (1 g/m2 every 12 hours on days l (Fig IF) . The karyotype was 46XY +(3) +(13)(q34), t(11;17)(q23;q21). The fibrinogen level was 1,300 mglL and the fibrin split products were detected at a dilution of 11160, indicating the presence of DIC. The patient received daunorubicin and Ara-C and achieved a CR after two treatment cycles. Maintainance therapy was administered using the same drugs, but the patient relapsed in April 1990, 7 months after the completion of therapy. A second remission was obtained with daunorubicin, Ara-C, and granulocytemacrophage colony-stimulating factor (GM-CSF). A second relapse occurred in April 1991 and a third remission was induced with etoposide and mitoxantrone. Maintanance therapy was administered consisting of monthly cycles of prednisone, vincristine, 6-mercaptopurine, and methotrexate, but in August 1991 a third relapse was noted. At that time, the WBC was 2.9 X 109L and the BM aspirate results showed 90% cellularity with 25% promyelocytes. The karyotype remained unchanged from that of the initial diagnosis. The patient received ATRA at a dose of 50 mg/mz/d and there was a steady increase in the WBC such that by day 10 of therapy the WBC was 29 X 109/L with 36% promyelocytes and 5% blasts. Repeat BM aspirate results then showed 74% promyelocytes. Idarubicin was administered at 12 mg/m*/d for 4 days, leading to only a transient decrease in the peripheral and marrow promyelocyte count. The patient then received fludarabine and Ara-C, with complications of congestive heart failure, DIC, and acute renal failure leading to the patient's death in December 1991.
Southern Blot Analysis
After receiving informed consent, BM aspirations were obtained from the patients and DNA was extracted as described."." The genomic DNA was digested with restriction enzymes as noted, electrophoretically separated through a 0.7% agarose gel, and transferred to nitrocellulose. A 5.5-kb EcoRI genomic fragment of the RARa gene or a 2.3-kb EamHVEgl I1 genomic fragment of the PLZF gene"' was labeled by the random priming method36 with a"P dCTP and allowed to hybridize to the filters in a solution of 5 X SSPE, 5X Denhardt's solution, 0.5% sodium dodecyl sulfate (SDS), 0.1 mg/ mL denatured salmon sperm DNA, and SO% formamide at 42°C. The filters were washed at a final stringency of 0.5X SSPE, 0.1 % SDS at 65°C for 15 minutes and exposed with an intensifying screen at -80°C for I to 5 days.
Pulsed-Field Gel Electrophoresis (PFGE)
BM mononuclear cells from a t(l1; 17) patient (case no. 3 ) or control patients were fractionated on Ficoll-Hypaque density gradients as recommended by the manufacturer (Pharmacia, Piscataway, NJ). The cells were then washed twice in l x phosphate-buffered saline (PBS) and the number of viable cells was determined by staining with 0.05% trypan blue exclusion. Agarose blocks containing the DNA were prepared as previously de~cribed.~'~'~ Fresh cells were resuspended at a concentration of 4 X IO7 cells/mL in T,,,EIOo (10 mmoV L Tris, pH 8.0, 1 0 0 mmol/L EDTA). Cell suspensions were mixed with an equal volume of molten 2% lnCert agarose ( W C , Rockland, ME) in T,,,E,,,, cooled to 42°C and 250-yL aliquots were distributed in wells of a plug mold (Bio-Rad, Richmond, CA). The plugs were allowed to solidify; were suspended in 10 mL of containing 1 % N-lauryl sarcosine (Sigma, St Louis, MO), 0.3 m o m 2-mercaptoethanol, and 200 pg/mL proteinase K; and were incubated at 55°C for 16 hours. Restriction endonucleases digestions were performed on the agarose-embedded DNA as described.37 PFGE was performed using 1% SeaKem GTG agarose ( M C ) in 0.5X TBE at 14°C in a contour-clamped homogeneous electric field of 6 V/cm (CHEF Mapper; Bio-Rad)." For a window of resolution of 25 to 400 kb, as used for separation of Sal I digests, the switch time was linearly ramped from 1.8 to 35.4 seconds for 20.3 hours. Saccharomyces cerevisicle chromosomes and phage X multimen sizes standards were obtained commercially (Bio-Rad). The separated DNA fragments were transferred to nitrocellulose and probed with a 2.3-kb a3'P-labeled genomic PLZF fragment or a 4.5-kb EamHUNot I genomic RARa fragment.iX All the hybridizations and washings were performed in a hybridization oven (Robbins Scientific Inc, Sunnyvale, CA), as described previously,'7 with the final wash performed at 42°C.
The blots were analyzed using a Phosphorimager and ImageQuant software (version 3.3; Molecular Dynamics, Sunnyvale, CA) and exposed with an intensifying screen at -80°C.
PCR for Detection of the PLZF-RARa Fusion mRNA
RNA was extracted from BM specimens using RNAzol (Chemex Biotech, Friendship, TX). Approximately 4 pg of RNA from each leukemic sample was hybridized to a primer (Primer-RT; Fig 3B) (S' TGGATGCTGCGGCGGAAGAAGCCCTTGCAG 3') complimentary to the B region of the RARa gene and reversed transcribed into cDNA by incubation with 200 U of Moloney murine leukemia virus (MMLV) reverse transcriptase (BRL, Bethesda, MD) at 37°C for 45 minutes. One tenth of the cDNA product was subsequently amplified by PCR using Taq polymerase (Promega, Madison, Wl) with a nested primer complimentary to the B region of RARa (5' GGGCACTATCTCTTCAG 3') (primer-3; Fig 3B) and a primer complimentary to the B region of PLZF (5' CTGTCTCCATGG-ACTTC 3') (primer-2; Fig 3B) or a primer complimentary to sequences more 5' in PLZF (S' GGAGCCAACTCTGGCTGGG 3') (primer-l; Fig 3B) as described." One tenth (10 pL) of the PCR products were electrophoretically separated through a 1.4% agarose gel and visualized by ethidium bromide staining of the gel. To further confirm the nature of the PCR products, a portion of each of the products was electrophoretically separated through an agarose gel. purified from the gel using glass beads (Gene Clean; Bio 101, La Jolla, CA), and subcloned into the TA cloning vector (Invitrogen. San Diego, CA). The subcloned fragments were sequenced on both strands using the dideoxy chain termination method (Sequenase; US Biochemicals, Cleveland, OH).
In Vitro Differentiation Assay
Cryopreserved leukemic blasts from case no. 5 and from a patient with classical M3, t(l5; 17) APL were thawed at 37°C in defrosting media (RPM1 1640, 20% fetal calf serum), centrifuged at 1,100 rpm for 5 minutes, and resuspended in the same media. Cells were cultured in the presence or absence of 10" m o m ATRA (Sigma) for 7 days. Aliquots of cells were removed at time 0, 2, S, and 7 days after initiation of culture for cytologic evaluation. Maturation was assessed by increase in the cytoplasmic/nuclear ratio, gain of nuclear segmentation, and loss of promyelocytic granules.
Graphics
Autoradiographs and photographs were imaged using a Silverscan flatbed digital scanner (La Cie, Ltd, Beaverton, OR). Ektachrome slides were imaged using a 35-mm Rapid Film Scanner (Eastman Kodak, Rochester, NY). Image processing was performed on a Macintosh Quadra 800 (Apple, Cupertino, CA) using Adobe Photoshop (Adobe, Mountain, CA) and Aldus Persuasion (Aldus, Seattle, WA) software. Figures were printed using an XL7700 Digital Continuous Tone Printer (Eastman Kodak).
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Table 1 summarizes the clinical features, molecular and cytogenetic findings, and clinical courses of the six patients. All six patients had the t( 11; 17) translocation on initial cytogenetic evaluation. Leukemic blasts from cases no. 1 and 2 were found to contain rearrangement and fusion of the RARa gene and PLZF gene as demonstrated by Southern blotting.30.32 Similarly, leukemic cells from case no. 4 had a rearrangement of the RARa gene yielding a 13.1-kb fragment that also hybridized to a cDNA probe for PLZF (Fig  2) . By RT/PCR analysis, the leukemic blasts of all six patients were found to produce a fusion transcript linking the PLZF and RARa (Fig 3A and data not shown). RNA from the BM of case no. 3 yielded a larger cDNA product by RTPCR than that produced from the index case (Fig 3A) . DNA sequence analysis of the fragment derived from case no. 3 indicated that its larger size was caused by the fusion of sequences encoding three rather than two zinc fingers of the PLZF gene to the region encoding the B domain of RARa (Fig 3B) . This finding suggests the presence of a novel breakpoint in the PLZF gene in case no. 3, most likely in an intron separating exons encoding zinc fingers 3 and 4 of the PLZF protein (Fig 4) . Preliminary analysis of the structure of the PLZF gene confirms that zinc fingers 3 and 4 of PLZF gene lie on different exons (Fig 4 and data  not shown) . Because all of the PLZF-RARa fusion products contained identical C-terminal RARa sequences (the B-F domains of RARa), in all six cases the breakpoint of the RARa gene was in the same general vicinity, occurring after the exon encoding the A1 domain of RARa and before the exon encoding the B domain of RARa. This is the same region in which the RARa gene is broken and rearranged with the PML gene in t(15;17) APL.34 In case no. 1, the breakpoint occurred 3' to the exon encoding the A2 domain of RARa, whereas in case no. 2, the breakpoint occurred 5' to the exon encoding the A2 domain (Fig 4) .30.32 For the other cases, more precise localization of the RARa breakpoint was not determined.
RESULTS AND DISCUSSION

Molecular Characterization of t(l l ; 17) Cases
PFGE
Despite the variable location of the t( 15; 17) breakpoint in t(l5; 17) APL, PFGE can detect the PML-RARa fusion gene in 100% of these cases using one restriction enzyme digestion and a single genomic DNA probe. 38 We extended this approach to the analysis of t(11; 17) translocation (Fig  5) . High molecular weight DNA from BM cells of a t( 11; 17) APL (case no. 3), from three non-APL, AML patients, and from the t(l5; 17) NB4 cell line4 was digested with Sal I. The resulting fragments were separated by PFGE, transferred to nitrocellulose, and hybridized to PLZF (Fig 5A) and RARa (Fig 5B) genomic probes. A 90-kb Sal I fragment cohybridized to PLZF and RARa probe (lane 1, Fig 5A and  B) , illustrating the t( 11; 17) translocation and confirming the presence of the PLZF-RARa fusion gene detected by RTI PCR analysis (Fig 3A) . In AML patients without t(l1; 17), this rearranged fragment was not detected with either probe (lanes 2 through 4, Fig 5) . In DNA from NB4 cells, the RARa probe detected a 70-kb rearranged fragment (lane 5, Fig 5B) , whereas the PLZF probe did not (compare lanes 1 and 5, Fig 5A) . As expected, the rearranged RARa fragment from the t( 15; 17) NB4 cells did cohybridize to a PML genomic probe (data not shown). In all lanes some extra high molecular weight fragments were noted, which is related to the incomplete digestion of genomic DNA by the methylation-sensitive Sal I enzyme. These data show that the DNAbased PFGE technique can be used to diagnose t( 1 1; 17) APL when RNA cannot be extracted from the specimen. This technique is not subject to false-positives caused by contamination, unlike PCR-based approaches to diagnosis. PFGE can also be used to identify novel rearrangements of the RARa gene when the identity of the fusion partner gene is not known.
Clinical and Pathologic Characterization
Clinically, most of the patients presented with features initially indistinguishable from classical APL. In general, the patients had a preponderance of promyelocytes in the initial BM aspirate and a relatively low peripheral WBC count ( Table l) . Cases no. 3, 5, and 6 presented with clinical and laboratory evidence of DIC. Case no. 4, although satisfying diagnostic criteria for AML, had a variety of early myeloid forms in the peripheral circulation, a feature associated with myeloproliferative disorders.
Case no. 4 was particularly interesting because it was found by immunophenotypic and molecular analysis to also be a member of a newly identified group of natural killer (NK)/myeloid leukemia." None of these patients had t( 15: 17) and only 1 patient of 20 (case no. 4) had t( 1 1 ; 17) and PLZF-RARa fusion. Morphologically, the leukemic blasts of these patients exhibit few granules and a peculiar deep nuclear invagination. Typically, these cells have the immunophenotype CD33'. CD13'. CD56', CD16-, HLADr-, CD34-. Expression of myeloid markers (CD33 and CD13) in conjunction with the absence of CD34 and HLADr expression is similar to the pattern seen in M3-AML. However, the leukemic blasts of case no. 4 and other cases of NWmyeloid leukemia also expressed an NK-associated marker, CD56 (N-CAM), and exhibited functional NK cellmediated cytotoxicity. CD33'. CD13', CD56', CD16-cells can be identified in the peripheral blood of normal individuals. It therefore appears that NWmyeloid leukemia results from the malignant transformation of a primative precursor cell common to both the myeloid and NK cell Iineage~.".~'
In five of six cases, the initial diagnosis by the referring pathologist was M3 AML. All of the morphologic material was reviewed by a single hematopathologist (D.R.H.) and compared with a series of 71 documented t( 15; 17) APL cases. All six t( 11; 17) cases, including case no. 4, consisted of a proliferation of myeloblasts more granular than the usual M2 AML, but less granular than the usual M3h (hypergranular) AML (Fig 1A through F cases to determine whether these cells express CD56. However, it would appear that in both diseases myeloid differentiation is blocked at a more primitive stage than classical M3 AML. Together, the morphologic data support the concept that t( 1 1; 17) APL is a clinicopathologic entity distinct from t( 15; 17) APL.
In Vitro Differentiation
In vitro differentiation studies were performed on mononuclear cells from patients no. 2, 4, and 5. In all three cases leukemic blasts failed to differentiate in the presence of IO" molL retinoic acid, whereas concomitant controls of promyelocytes from patients with t(15; 17) APL did3* (Fig 6 and  data not shown) . Cells from case no. 5 failed to exhibit morphologic evidence of differentiation (Fig 6A and B) , whereas a concurrent control of leukemic cells derived from a t(l5; 17) patient did (Fig 6C and D) . It was previously shown that optimal differentiation of fresh leukemic samples could be achieved at IO" molL ATRA!2 Incubation of cells from cases no. 2 and 5 with a IO-fold higher concentration of ATRA (IO-' molL) still did not induce differentiation. The failure of leukemic cells from t( 1 I ; 17) patients to differentiate in vitro correlated with the inability of ATRA to induce a clinical response in these patients. These data support the utility of the in vitro differentiation assay as predictor of clinical response to ATRA.
Response to Treatment
Despite the superficial morphologic similarity of the t(15; 17) and t( 1 1; 17) patients, the latter group with fusion of the PLZF and RARcv genes generally responded poorly to treatment. One of the six patients is currently in CR after salvage therapy and a second died at 3 1 months after multiple short remissions and relapses. In contrast, classical t( 15; 17) APL is characterized by a 60% to 80% response rate to conventional chemotherapy, a similar 75% to 95% CR rate with ATRA therapy, and a 5-year survival rate of 35% to 45%.14 Five of the six patients with t( 11; 17) APL received ATRA at some time during their clinical course, but none had a clinically significant response to the agent (Table 1) . Cases no. 1 and 3 were initially treated with ATRA, whereas case no. 2 received this agent after failing to respond to induction therapy with daunorubicin and Ara-C. Case no. 1 died early in the clinical course of respiratory failure with a highly elevated leukocyte count. In retrospect, this patient may have suffered from the retinoic acid syndrome'.' characterized by a proliferation of leukemic cells with resulting pulmonary leukostasis. In t(15; 17) patients, this hyperproliferative effect may preceed the clinical response characterized by the induction of differentiation of the leukemic promyelocytes. Case no. 2 also had evidence of some response to ATRA because there was a decline in the number of promyelocytes in the BM while on therapy, but, unlike patients with t( 15; l7), this patient did not achieve morphologic or cytogenetic remission. Because blasts from this patient did not differentiate when cultured in the presence of ATRA in vitro,32 the clinical response to ATRA may have been antiproliferative in nature. Similarly, in case no. 3, administration of ATRA was associated with a decline in the promyelocyte count and improvement of biochemical parameters indicative of DIC. However, this patient died early in the clinical course of a bleeding complication. Case no. 4 was treated only with chemotherapy and did not respond to initial therapy with daunorubicin and Ara-C, but achieved a brief remission with second-line therapy with mitoxantrone and etoposide and appeared to convert to a chronic myeloid leukemia (CML)-like syndrome. Case no. 5 received combination chemotherapy and ATRA therapy on a randomized protocol with no evidence of response. After initiation of ATRA therapy, case no. 6 experienced an increase in the promyelocyte count, but this was not followed by evidence of differentiation. Case no. 6 was identified among a series of patients with APL in relapse after initial treatment with chemotherapy!3 Although 14 of 17 (82%) of these patients completely responded to ATRA and idarubicin as a second-line therapy, case no. 6 was among the 3 that did not. We conclude that APL morphology elements, the ability to act as an RA-dependent transcription factor, and the ability to antagonize the function of the wildtype RARa. The ability of the PML-RARa and PLZF-RARa fusion proteins to antagonize wild-type RARa function may explain why the two syndromes have the same cytologic morphology.
Treatment oft( 11;7) leukemic cells in vitro with IO times more ATRA (IO-' mol/L) than required for optimal induction of t( 15; 17) cells failed to induce differentiation. However, the PLZF-RARa and PML-RARa fusion proteins mediate similar amounts of transcription in response to IO-' mol/L ATRA, which is reduced compared with wild-type RARa (R. Shaknovich, M. English, J. Licht, manuscript in preparation). Therefore, it is difficult to explain why only the disease associated with t( IS; 17) and PML-RARa fusion responds well to ATRA. The key to this problem is to understand the role of the PML and PLZF genes in myeloid development and how the functions of these genes are affected by fusion to the RARa gene.
In this regard, it must be stressed that there are considerable differences between the PML and PLZF genes. PML is a ubiquitously expressed gene7 that encodes a member of an enlarging family of proteins with an unusual cysteine-rich cluster termed the "ring" finger." In at least some cases this motif is used for binding to nucleic acids. However, PML has an unusual nuclear localization in an average of I O small concentric structure called nuclear bodies47 or PML onocogenic domains (PODS).'~ These bodies do not appear to colocalize with sites of RNA transcription or splicing and their function is unknown.?X~J" In t( 15; 17) APL cells, the PML protein is abnormally localized in hundreds of small nuclear body onf figuration^^"^ PML also appears to have tumor suppressor activity. PML overexpression in t( IS; 17)-containing NB4 cellsJ" reduces the clonogenicity of these cells in soft agar and their tumorgenicity in nude mice."' In addition, PML suppresses oncogenic transformation of rat embryo fibroblast cells cotransfected with the ras and myc oncogenes.'" These data suggest that PML acts as a governor of normal cell proliferation and that the function of PML is disrupted by fusion to the RARa protein, perhaps by the aberrant localization of PML away from the nuclear body structure. According to this hypothesis, ATRA treatment restores the normal localization of PML in t( 15; 17) APL cells and leads to the cessation of cell growth and onset of differentiation. This notion is supported by the discovery of an ATRA-resistant cell line that fails to relocalize PML and PML-RARa protein upon treatment with ATRA.4R In t( 15; 17) APL, a reciprocal fusion protein RARa-PML is also generated and is found to be localized to the nucleus.'6 However, no clear role for this fusion protein has been assigned to this protein in leukemogenesis.
In contrast to the PML gene, the PLZF gene is expressed in a tissue-specific manner, particularly in the myeloid lineage.'" The PLZF protein is a member of the large family of cysteine-and histidine-containing zinc finger transcription factors" typified by the Drosophila Kriippel proteid' and encoded by human oncogenes such as GI?' and tumor suppressors genes such as WTI."J.~~ Preliminary data indicate that the PLZF protein, although localized to the nucleus, is not found in nuclear body structures (R. Shaknovich and J. Licht, manuscript in preparation). Furthermore, it appears that the PLZF protein has specific DNA binding and trandomains in the nucleus, apparently because of the action of scriptional effector activities (J. Li, M. English, and J. Licht, the PML-RARa fusion protein. Upon addition of ATRA to manuscript in preparation). Therefore, PLZF is likely to be APL cells the PML protein relocalizes into the wild-type a transcription factor that regulates genes required for white LlCHT ET AL blood cell development. The expression of the wild-type PLZF gene decreases during ATRA-mediated myeloid differentiati~n.'~ Hence, the genes targeted by the PLZF transcription factor would be expected to be differentially regulated during differentiation. In t( 11; 17) and fusion of the PLZF and RARa genes, a PLZF-RARa fusion protein is generated linking two or three zinc fingers of the PLZF protein to the RARa. This protein, in addition to acting as an RA-responsive transcription factor, could also bind to DNA targets through the PLZF zinc fingers. Perhaps more importantly, the reciprocal fusion protein generated in t( 1 1 ; 17) links DNA encoding the last 7 zinc fingers of PLZF to the RARa gene, including the RARa promoter. The resulting RARa-PLZF protein contains the last 7 of the 9 zinc fingers of the PLZF protein and may bind the same target genes as the wild-type protein. The RARa-PLZF fusion gene would be expected to be constitutively expressed during myeloid differentiation, paralleling the pattern of expression of the wild-type RARa and could act as a dominant negative inhibitor of wild-type PLZF. This effect could even be enhanced by ATRA therapy because the RARa promoter is activated by ATRA treatment of myeloid and other ~e l l s .~~,~' This hypothesis predicts that disruption of the wild-type PLZF gene rather than interference with RARa function may be critical for the most important clinical feature of t( 11; 17) APL, namely its failure to respond to ATRA therapy.
There has been at least one prior case of APL associated with t(11;17) (q21.12/21)58 as well as a recent report of t(5; 17) and RARa translocation associated with APL.59 This latter case re-emphasizes the importance of disruption of RARa in generating the promyelocyte phenotype. Given that more than 90% of APL cases are associated with t(15; 17), it appears that rearrangement of the RARa locus with genes other than the PML gene on chromosome 15 is a rare event. Nevertheless, given the grave natural history of leukemia associated with t( 11; 17), it is important to identify these patients and select them for aggressive and novel treatment approaches. RA has antiproliferative as well as differentiative effects that have been observed in non-M3 AML patientsm Given that two of the six t( l l ; 17) patients had significant declines in promyelocyte count with ATRA therapy, it may be useful to pursue novel methods to enhance the efficacy of ATRA6"65 in these patients. Alternatively, patients with t(l l ; 17) APL might be treated with aggressive myeloablative chemotherapy and BM transplantation early in the course of their disease.
